The Center for Global Health Policy’s “Science Speaks” blog examines the use of daily oral pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among men who have sex with men (MSM). “…Of all the recent advancements that have been shown to be effective in preventing HIV, daily oral pre-exposure prophylaxis (PrEP) has been shown to be the most efficacious prevention method for men who have sex with men, after condoms. The landmark iPrEx trial demonstrated 41 percent efficacy among men who have sex with men and transgender women with a regimen that includes Truvada…” However, “only the U.S. has approved the use of daily oral Truvada PrEP for men who have sex with men and others at risk, but no other country that participated in iPrEx, including Thailand, Peru, Brazil, and South Africa, has followed…” (2/4).